FOLH1 and neoplasm: Firstly, different tumour entities and radiopharmaceuticals have been investigated (mCRPC vs. NETs/meningioma; [177Lu]Lu-PSMA I&T vs. [177Lu]Lu-DOTATATE/DOTATOC).